Roche Holding AG completed its tender offer to acquire Ignyta Inc. shares for $27 each.
Some 57,372,887 shares representing 84.71% of the California-based cancer specialist were tendered to Roche's offer. Another 3,453,623 shares have also been tendered to the offer and are pending delivery.
The Swiss pharmaceuticals and diagnostics company agreed to fully acquire Ignyta in an all-cash deal valued at $1.7 billion in December 2017.
Citi and Sidley Austin LLP acted as financial adviser and legal counsel to Roche, respectively.
Bank of America Merrill Lynch and J.P. Morgan Securities LLC were Ignyta's financial advisers, while Latham & Watkins LLP was the company's legal counsel.
